Astellas Pharma Inc. continues to build up a regenerative medicine portfolio, most recently paying $80m up front to develop and commercialize Frequency Therapeutics Inc.'s one-and-only clinical drug candidate – FX-322 for hearing loss – in ex-US markets.
The deal announced on 17 July also gives Woburn, MA-based Frequency up to $545m in development and commercial milestone fees...








